| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.05 | 0.4 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | -0.042 | 0.4 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.4 |